Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9C026
UPID:
TRIM9_HUMAN
Alternative names:
RING finger protein 91; RING-type E3 ubiquitin transferase TRIM9; Tripartite motif-containing protein 9
Alternative UPACC:
Q9C026; D3DSB7; D3DSB8; Q92557; Q96D24; Q96NI4; Q9C025; Q9C027
Background:
E3 ubiquitin-protein ligase TRIM9, also known as RING finger protein 91 and Tripartite motif-containing protein 9, plays a pivotal role in neuronal functions. It ubiquitinates itself in cooperation with UBE2D2/UBC4, targeting itself for proteasomal degradation. This process is crucial for the regulation of synaptic vesicle exocytosis, influencing the availability of SNAP25 for SNARE complex formation.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM9 could open doors to potential therapeutic strategies.